<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOph</journal-id><journal-title-group><journal-title>Open Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2165-7408</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojoph.2017.73021</article-id><article-id pub-id-type="publisher-id">OJOph-77497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Retinal Damage of Hemoglobinopathies in Adults: About 181 Cases in Campus-Teaching Hospital of Lom&#233;
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nidain</surname><given-names>Maneh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Koffi</surname><given-names>Didier Ayena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kossi</surname><given-names>Brice Dzidzinyo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kokou</surname><given-names>Vonor</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Komi</surname><given-names>Patrice Balo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Faculty of Health Sciences University of Lomé, Lomé, Togo</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>manehnid@hotmail.fr(NM)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>07</month><year>2017</year></pub-date><volume>07</volume><issue>03</issue><fpage>153</fpage><lpage>157</lpage><history><date date-type="received"><day>April</day>	<month>28,</month>	<year>2017</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>July</month>	<year>7,</year>	</date><date date-type="accepted"><day>July</day>	<month>10,</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Aims: To study the frequency of sickle cell retinopathy and its severity. Material and Methods: Retrospective study over a period of 3 years (July 2013 thru June 2016) of cases of adults over 18 years old sent by the Hematology Department of the Campus-Teaching Hospital of Lom&#233; in the context of a sickle-cell disease check-up. The parameters studied were age, sex, genotype, examination of the fundus by the Goldmann lens. The classi-fication after the fundus was in non-proliferative retinopathy and in 5 proliferative stages according to Goldberg’s classification. Results: Hundred and eighty-one patients were included with an average age of 29.39 &#177; 9.84. The sex ratio was 0.72 in favor of female. The SC genotype was 50.3%; SS 37.6%; CC 11% and SF 1.1%. Sickle cell retinopathy was found in 22.7% of patients, among which 14.4% were proliferative and 8.3% non-proliferative. Seventy-three percent of patients with proliferative retinopathy were SC genotype, 23% SS and 3% CC genotype. Among SC patients, 20.9% had proliferative retinopathy; 8.8% SS; and 5% CC. Fifty percent of patients with proliferative retinopathy had Goldberg’s stage ≥ 3. Conclusion: We found 22.7% of sickle cell retinopathy which proliferative form was strongly represented by the SC genotype.
 
</p></abstract><kwd-group><kwd>Hemoglobinopathy</kwd><kwd> Sickle Cell Retinopathy</kwd><kwd> Adult</kwd><kwd> Lom&#233;</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Hemoglobinopathies are due to the appearance of the pathological hemoglobin through structural modification of certain polypeptide chains of the normal hemoglobin (HbA). Sickle-cell disease is a frequent and severe hemoglobinopathy. About 230,000 children affected by sickle-cell disease are born every year in the sub-Saharan region, 2600 in North America and 1300 in Europe [<xref ref-type="bibr" rid="scirp.77497-ref1">1</xref>] . The molecular mechanism is the replacement of the glutamic acid by valine at the level of the codon 6 of the β globin gene, resulting in the production of the abnormal hemoglobin, hemoglobin S (HbS). Sickle cell disease is transmitted through the autosomal recessive mode: homozygote SS, heterozygote AS, double heterozygotes or “composite heterozygotes” SC (AS + AC), Sβ (AS + β heterozygote thalassemia).</p><p>AS heterozygotes are asymptomatic, SS homozygotes and double heterozygotes or “composite heterozygotes” SC, Sβ, SS + HPFH (hereditary persistence of fetal hemoglobin) are symptomatic and show the systemic manifestations of this disease. The ocular manifestations of sickle-cell disease are frequent and especially retinal with complications potentially associated with visual loss. Sickle cell retinopathy is frequently described in SS and SC homozygous forms and more rarely in AS [<xref ref-type="bibr" rid="scirp.77497-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.77497-ref3">3</xref>] and Sβ [<xref ref-type="bibr" rid="scirp.77497-ref4">4</xref>] heterozygous forms. The study of Balo et al. [<xref ref-type="bibr" rid="scirp.77497-ref2">2</xref>] in Lom&#233; showed that AS form was the most affected by retinopathy in 26.3%, followed by SS group in 11.05%.</p><p>The present study determines the frequency and severity of retinopathy among patients referred for ophthalmologic consultation by the Hematology Department, a reference unit for hemoglobinopathies care in Togo.</p></sec><sec id="s2"><title>2. Material and Methods</title><p>This retrospective study over a period of three years (July 2013 thru June 2016) focused on the records of consecutive patients who are over 18 years old, sent to the Department of Ophthalmology for retinopathy by the Hematology Department. The diagnosis of sickle cell disease and genotypic accuracy were previously specified by the hematologist after hemoglobin electrophoresis: homozygote SS, heterozygote AS, double heterozygotes or “composite heterozygotes” SC (AS + AC), HPFH (hereditary persistence of fetal hemoglobin). All patients had a slit-lamp examination, the fundus by the Goldmann lens to assess the posterior pole and the entire retinal periphery. A distribution in the absence of sickle cell retinopathy, in non-proliferative sickle cell retinopathy (golden frosted, black sunburst) and in proliferative form according to Goldberg’s classification (Goldberg 1: peripheral arteriolar occlusions, Goldberg 2: peripheral arterio- venular anastomoses, Goldberg 3: preretinal peripheral neovascularization, Goldberg 4: intravitreal hemorrhage, Goldberg 5: retinal detachment) [<xref ref-type="bibr" rid="scirp.77497-ref5">5</xref>] had been made.</p><p>Patients with AS sickle-cell, an associated β-thalassemia or α-thalassemia were excluded from the study. The parameters analyzed in the study were age, sex, genotype (SS, SC, SF, and CC), and the severity of the retinopathy (non-proli- ferative and according to Goldberg).</p><p>The statistical analysis, χ<sup>2</sup> was carried out through Epi info software version 7.0 with a significance p &lt; 0.05. For qualitative variables, a 95% confidence interval (CI) was calculated.</p></sec><sec id="s3"><title>3. Results</title><p>Hundred and eighty-one patients among whom 105 women and 76 men (sex ratio = 0.72) were included in the study. The average age was 29.4 &#177; 9.84 years; [18 years; 70 years] <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>Ninety-one patients were SS genotype (50.3%), sixty eight were SC (37.6%), twenty CC genotype and 2 were SF (1.1%) <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p>Fifteen patients (8.3% CI [4.7 - 13.3]) showed a non-proliferative retinopathy (8 SS, 7 SC) and twenty-six patients (14.4% CI [9.6 - 20.3]) a proliferative sickle cell retinopathy.</p><p>Out of the twenty-six patients with the proliferative retinopathy, nineteen patients were SC genotype (20.9% of the SC), six patients were SS genotype (8.8% of the SS) and one patient of CC genotype (5% of the CC). 17.1% of female and 10.5% of male showed a PSR (Proliferative Sickle cell Retinopathy) <xref ref-type="table" rid="table2">Table 2</xref>. The average age of patients with a PSR form was 34 &#177; 8.5 years [18 years; 53 years].</p><p>These proliferative retinopathies were predominantly of stage 2 (34.6%), stage 3 (30.8%) and stage 4 (15.4%). The severe forms of proliferative retinopathy with a Goldberg’s stage ≥ 3 were found in 13 patients. Seventy-five percent of male (5 cases) with proliferative retinopathy had a severe form, and 38.9% (7 cases) of female had a severe form. Eleven of the severe forms were SC genotype (57.9%) and 2 were SS genotype (33.3%) <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The socio-demographic characteristics of the patients: age (years) and sex (female, male)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Female</th><th align="center" valign="middle" >Male</th><th align="center" valign="middle" >Total</th></tr></thead><tr><td align="center" valign="middle" >[18 - 35[</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >138</td></tr><tr><td align="center" valign="middle" >[35 - 45[</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >29</td></tr><tr><td align="center" valign="middle" >[45 - 55[</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >&gt;55</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >105</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >181</td></tr></tbody></table></table-wrap><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Distribution of the different genotypes</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/2-2020265x2.png"/></fig><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of genotypes according to the severity of the retinopathy</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  rowspan="2"  >Absence<sup>#</sup></th><th align="center" valign="middle"  rowspan="2"  >Non-proliferative retinopathy</th><th align="center" valign="middle"  colspan="6"  >Proliferative retinopathy (%)</th></tr></thead><tr><td align="center" valign="middle" >Stage 1</td><td align="center" valign="middle" >Stage 2</td><td align="center" valign="middle" >Stage3</td><td align="center" valign="middle" >Stage 4</td><td align="center" valign="middle" >Stage 5</td><td align="center" valign="middle" >Severe 3 + 4 + 5</td></tr><tr><td align="center" valign="middle" >SS</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2 (33.3)</td></tr><tr><td align="center" valign="middle" >SC</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >11 (57.9)</td></tr><tr><td align="center" valign="middle" >CC</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >SF</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >140 (77.3)</td><td align="center" valign="middle" >15 (8.3)</td><td align="center" valign="middle"  colspan="5"  >26 (14.4)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p><sup>#</sup>Absence of retinopathy.</p></sec><sec id="s4"><title>4. Discussion</title><p>The absence of retinal angiography was a limit to our study.</p><p>In our study, we found a large proportion of the SS form (50.3%) followed by the SC form (37.6%) as reported in several studies [<xref ref-type="bibr" rid="scirp.77497-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.77497-ref7">7</xref>] . The study of Diallo et al. had reported in its series a predominance of the SC form in 79.8% then the SS form 20.2% [<xref ref-type="bibr" rid="scirp.77497-ref8">8</xref>] . Fourteen point four percent (14.4%) had proliferative sickle cell retinopathy, which was low compared to that of Diallo et al. [<xref ref-type="bibr" rid="scirp.77497-ref8">8</xref>] with 20% and Tran et al. [<xref ref-type="bibr" rid="scirp.77497-ref7">7</xref>] with 59%. These differences may be due to the selection criteria because the majority of our patients were already followed in the Hematology Department. The study showed that SC form was the most represented in the proliferative forms 20.9% SC vs. 8.8% SS; as in the review 22% to 43% SC vs. 14% SS [<xref ref-type="bibr" rid="scirp.77497-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.77497-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.77497-ref11">11</xref>] . SC form was also the most represented in the severe proliferative forms (57.9% SC vs. 33.3%SS) like in the study of Leveziel et al. [<xref ref-type="bibr" rid="scirp.77497-ref6">6</xref>] 54.4% SC vs. 18.1% SS. This confirms the findings that SC forms give retinal complications. In our study, male (75%) showed the severe forms more than female (38.9%). Male sex is a promoting factor for proliferation, as well as hemoglobin level higher than 12.5 g; blood hyperviscosity, hypoxemia, precarious medical treatment [<xref ref-type="bibr" rid="scirp.77497-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.77497-ref13">13</xref>] .</p></sec><sec id="s5"><title>5. Conclusion</title><p>Proliferative retinopathy was mainly found in SC genotype. More than half of proliferative sickle-cell retinopathies were severe with a male dominance. An early hematologic and ophthalmologic management and a regular follow-up will enable the reduction of blinding retinal complications.</p></sec><sec id="s6"><title>Conflict of Interest</title><p>The authors declare no conflict of interest.</p></sec><sec id="s7"><title>Ethical Approval</title><p>Approval for the study was obtained from the national medical ethic committee.</p></sec><sec id="s8"><title>Cite this paper</title><p>Maneh, N., Ayena, K.D., Dzidzinyo, K.B., Vonor, K. and Balo, K.P. (2017) Retinal Damage of Hemoglobinopathies in Adults: About 181 Cases in Cam- pus-Teaching Hospital of Lom&#233;. Open Journal of Ophthalmology, 7, 153-157. https://doi.org/10.4236/ojoph.2017.73021</p></sec></body><back><ref-list><title>References</title><ref id="scirp.77497-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Modell, B. and Darlison, M. (2008) Global Epidemiology of Haemoglobin Disorders and Derived Service Indicators. Bulletin of the World Health Organization, 86, 480-487. https://doi.org/10.2471/BLT.06.036673</mixed-citation></ref><ref id="scirp.77497-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Balo, K.P., Fany, A., Mihluedo, H., Djagnikpo, P.A. and Koffi-Gue, K.B. (1997) Atteinte rétinienne dans la drépanocytose au Togo: Corrélation entre l’age, le génotype et la rétinopathie. Journal Franais d’Ophtalmologie, 20, 653-658.</mixed-citation></ref><ref id="scirp.77497-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fany, A., Boni, S., Adjorlolo, C., et al. (2004) La rétinopathie chez le porteur du trait drépanocytaire AS: Mythe ou réalité? Journal Franais d’Ophtalmologie, 27, 1025-1030. https://doi.org/10.1016/S0181-5512(04)96259-6</mixed-citation></ref><ref id="scirp.77497-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Fany, A., Coulibaly, F., Gbe, K., et al. (2005) Les bêta thalassos drépanocytoses pourvoyeuses de rétinopathie ischémiques graves. Journal Franais d’Ophtalmologie, 28, 391-395. https://doi.org/10.1016/S0181-5512(05)81070-8</mixed-citation></ref><ref id="scirp.77497-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Goldberg, M.F. (1971) Classification and Pathogenesis of Proliferative Sickle Retinopathy. American Journal of Ophthalmology, 71, 649-665.  
https://doi.org/10.1016/0002-9394(71)90429-6</mixed-citation></ref><ref id="scirp.77497-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Leveziel, N., Lallouma, F., Bastuji-Garinc, S., et al. (2012) Rétinopathie drépanocy-taire: Analyse rétrospective portant sur 730 patients suivis dans un centre de référence. Journal Franais d’Ophtalmologie, 35, 343-347.  
https://doi.org/10.1016/j.jfo.2011.10.007</mixed-citation></ref><ref id="scirp.77497-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tran, T.H.C., Mekinian, A., Godinaud, M. and Rose, C. (2008) Rétinopathie drépanocytaire chez les adultes de la région Nord-Pas-de-Calais. Journal Franais d’Ophtalmologie, 31, 987-992. https://doi.org/10.1016/S0181-5512(08)74745-4</mixed-citation></ref><ref id="scirp.77497-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Diallo, J.W., Sanfo, O., Blot, I., et al. (2009) Etude épidémiologique et facteurs pronostiques de la rétinopathie drépanocytaire à Ouagadougou (Burkina Faso). Journal Franais d’Ophtalmologie, 32, 496-500.  
https://doi.org/10.1016/j.jfo.2009.04.010</mixed-citation></ref><ref id="scirp.77497-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Babalola, O.E. and Wambebe, C.O. (2005) Ocular Morbidity from Sickle Cell Disease in a Nigerian Cohort. Nigerian Postgraduate Medical Journal, 12, 241-244.</mixed-citation></ref><ref id="scirp.77497-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Powars, D.R., Hiti, A., Ramicone, E., Johnson, C. and Chan, L. (2002) Outcome in Hemoglobin SC Disease: A Four-Decade Observational Study of Clinical, Hematologic, and Genetic Factors. American Journal of Hematology, 70, 206-215.  
https://doi.org/10.1002/ajh.10140</mixed-citation></ref><ref id="scirp.77497-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Powars, D.R., Chan, L.S., Hiti, A., Ramicone, E. and Johnson, C. (2005) Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients. Medicine (Baltimore), 84, 363-376. https://doi.org/10.1097/01.md.0000189089.45003.52</mixed-citation></ref><ref id="scirp.77497-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morel</surname><given-names> C. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Atteintes rétiniennes des hémoglobinopathies</article-title><source> Journal Franais d’Ophtalmologie</source><volume> 24</volume>,<fpage> 987</fpage>-<lpage>992</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.77497-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hayes, R.I., Condon, P.I. and Serjeant, G.R. (1981) Hematological Factors Associated with Proliferative Retinopathy in Homozygotes Sickle Cell Disease. British Journal of Ophthalmology, 65, 29-35. https://doi.org/10.1136/bjo.65.1.29</mixed-citation></ref></ref-list></back></article>